| Identification | Back Directory | [Name]
Benzoic acid, 3-[[4-[4-(aminoiminomethyl)benzoyl]-1-piperazinyl]carbonyl]-5-[[4-(aminoiminomethyl)-1-piperazinyl]methyl]-, methyl ester, hydrochloride (1:3) | [CAS]
2070015-03-9 | [Synonyms]
Benzoic acid, 3-[[4-[4-(aminoiminomethyl)benzoyl]-1-piperazinyl]carbonyl]-5-[[4-(aminoiminomethyl)-1-piperazinyl]methyl]-, methyl ester, hydrochloride (1:3) | [Molecular Formula]
C27H34N8O4.3ClH | [MOL File]
2070015-03-9.mol | [Molecular Weight]
643.99 |
| Hazard Information | Back Directory | [Uses]
CBB1007 trihydrochloride is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).
IC50 Value: 5.27 uM
Target: hLSD1
CBB1007 efficiently can block LSD1-mediated demethylation of H3K4Me2 and H3K4Me (IC50 ≤ 5 μM) with no effect on H3K4Me3 and H3K9Me2, and LSD2 and JARID1A activities. Increases H3K4Me2 and H3K4Me contents (IC50 ≤ 5 μM), and causes activation of epigenetically suppressed CHRM4/M4-ArchR and SCN3A genes in F9 cells (IC50 ≤ 3.74 μM). CBB1007 was Shown to preferentially arrest the growth of pluripotent tumors with minimal effect on non-pluripotent cancer or normal somatic cells (IC50 ≥ 100 μM). | [IC 50]
KDM1/LSD1 | [References]
[1] Wang J, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011 Dec 1;71(23):7238-49. DOI:10.1158/0008-5472.CAN-11-0896 |
|
|